ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Vertex, Ribometrix to develop RNA-targeted small molecules

by Lisa M. Jarvis
October 6, 2019 | APPEARED IN VOLUME 97, ISSUE 39

 

Vertex Pharmaceuticals will pay Ribometrix $20 million to develop up to three RNA-targeted small-molecule treatments. The partners are not identifying drug targets, but Ribometrix previously disclosed to C&EN that it is pursuing molecules that bind to messenger RNA related to the cancer driver c-Myc and that target mRNA connected with the protein implicated in Huntington’s disease. Ribometrix was founded in 2017 based on discoveries of chemist Kevin Weeks at the University of North Carolina at Chapel Hill.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment